Atefeh Zamani
Research Subjects
Atefeh Zamani has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Mahdevar
Department of Genetics and Molecular biology, School of Medicine, Isfahan University of Medical sciences
11 shared publications Ensieh Sagheb Sadeghi
Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
5 shared publicationsBehnoosh Nikonezhad
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
2 shared publicationsFarnoosh Akbari
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
2 shared publicationsMohammad Hadi Masuomi
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
2 shared publicationsAli Karimi
Genius Gene, Genetics and Biotechnology Company, Isfahan, Iran
1 shared publication
Latest Publications
- 27 August 2026
- Published by Springer Nature in Current Genetic Medicine Reports
- Vol. 14 (1) , 33
Elevated Expression of LINC02257 and LINC00659 in Breast Cancer is Associated with Poor Survival and Immune Cell Infiltration
- 27 August 2026
- Published by Springer Nature in Current Genetic Medicine Reports
- Vol. 14 (1) , 33
Elevated Expression of LINC02257 and LINC00659 in Breast Cancer is Associated with Poor Survival and Immune Cell Infiltration
- Open Access
- 20 February 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
ZnO@Carvacrol nanoparticles effectively suppress biofilm and quorum-sensing mechanisms in MDR Acinetobacter baumannii
Multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) is a serious public health concern. This is mainly due to its strong biofilm formation and
- 20 February 2026
- Published by Springer Nature in BMC Microbiology
- Vol. 26 (1)
Open AccessZnO@Carvacrol nanoparticles effectively suppress biofilm and quorum-sensing mechanisms in MDR Acinetobacter baumannii
Multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) is a serious public health concern. This is mainly due to its strong biofilm formation and
- Open Access
- 30 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Silencing TMEM105 suppresses gastric cancer cell growth and migration via proliferation-associated pathways
Numerous studies in the field of cancer indicate that long non-coding RNAs (lncRNAs) play a significant role in the development and malignancy of various c
- 30 December 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessSilencing TMEM105 suppresses gastric cancer cell growth and migration via proliferation-associated pathways
Numerous studies in the field of cancer indicate that long non-coding RNAs (lncRNAs) play a significant role in the development and malignancy of various c
- 5 December 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (4) , 5526-5540
Candidate Prognostic LncRNAs Including C2orf49-DT, CAPN10-DT, LOC105371795 as Potential Biomarkers for Colorectal Cancer
Long non-coding RNAs (lncRNAs) have regulatory functions and are linked to various disorders, including cancer. In this study, we investigated signature lncRNAs that may be associated with the pathogenesis of colorectal cancer (CRC) and could serve as diagnostic and prognostic biomarkers. The relationship between lncRNA expression and patient mortality rates was identified using data from The Cancer Genome Atlas. Next, linear models determined the differential expression of lncRNAs in cancer and healthy samples. The association of lncRNA expression with patient prognosis was examined using a Cox regression test, and the risk model was constructed using a subset of lncRNAs. The co-expression network was analyzed to identify the pathways associated with candidate lncRNAs. The expression levels of specific lncRNAs were examined in 35 tumor samples from the Iranian Tumor Bank to validate the in-silico analyses. RNAs were extracted using TRIzol, and their quality was assessed. The qRT-PCR method determined candidate gene expression levels after cDNA synthesis. Our findings showed that C2orf49-DT, CAPN10-DT, and LOC105371795 levels were higher in CRC samples and linked to patients with poor prognoses. The co-expression network data demonstrated that the examined lncRNAs were connected to crucial genes involved in cell proliferation, like E2F3. The RT-qPCR results showed a significant increase in C2orf49-DT, CAPN10-DT, and LOC105371795 compared to healthy tissue samples. We found a significant correlation between the levels of the mentioned lncRNAs and E2F3 expression in the ex vivo data. Our findings suggest that elevated levels of C2orf49-DT, CAPN10-DT, and LOC105371795 may be associated with increased mortality rates in CRC patients. These non-coding RNAs are associated with pathways that promote cell proliferation and are proposed as potential biomarkers for diagnosing and predicting CRC.
- 5 December 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 64 (4) , 5526-5540
Candidate Prognostic LncRNAs Including C2orf49-DT, CAPN10-DT, LOC105371795 as Potential Biomarkers for Colorectal Cancer
Long non-coding RNAs (lncRNAs) have regulatory functions and are linked to various disorders, including cancer. In this study, we investigated signature lncRNAs that may be associated with the pathogenesis of colorectal cancer (CRC) and could serve as diagnostic and prognostic biomarkers. The relationship between lncRNA expression and patient mortality rates was identified using data from The Cancer Genome Atlas. Next, linear models determined the differential expression of lncRNAs in cancer and healthy samples. The association of lncRNA expression with patient prognosis was examined using a Cox regression test, and the risk model was constructed using a subset of lncRNAs. The co-expression network was analyzed to identify the pathways associated with candidate lncRNAs. The expression levels of specific lncRNAs were examined in 35 tumor samples from the Iranian Tumor Bank to validate the in-silico analyses. RNAs were extracted using TRIzol, and their quality was assessed. The qRT-PCR method determined candidate gene expression levels after cDNA synthesis. Our findings showed that C2orf49-DT, CAPN10-DT, and LOC105371795 levels were higher in CRC samples and linked to patients with poor prognoses. The co-expression network data demonstrated that the examined lncRNAs were connected to crucial genes involved in cell proliferation, like E2F3. The RT-qPCR results showed a significant increase in C2orf49-DT, CAPN10-DT, and LOC105371795 compared to healthy tissue samples. We found a significant correlation between the levels of the mentioned lncRNAs and E2F3 expression in the ex vivo data. Our findings suggest that elevated levels of C2orf49-DT, CAPN10-DT, and LOC105371795 may be associated with increased mortality rates in CRC patients. These non-coding RNAs are associated with pathways that promote cell proliferation and are proposed as potential biomarkers for diagnosing and predicting CRC.
- Open Access
- 6 June 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-14
Insights into the E2F target genes in breast cancer: associations of pathway genes with prognosis and immune cell filtration based on in silico and ex vivo analyses
E2F transcription factors are crucial in various biological processes, including cell proliferation, differentiation, and apoptosis. However, the exact role of E2F target genes in breast cancer (BC), as well as their influence on survival and immune response, remains poorly understood. To investigate the differential expression of E2F target genes and their relationship with patient prognosis and immune cell infiltration, transcriptomic data from the Cancer Genome Atlas database were analyzed. A risk model was developed to identify genes associated with survival. BC samples were clustered into high-expression (C1) and low-expression (C2) groups of E2F target genes. The correlation between gene expression and factors such as survival, immune cell infiltration (CD4 + and CD8 + T cells), and immune checkpoint inhibitors (PD-L1 and PD-L2) was analyzed. We analyzed the link between clusters and clinical characteristics using the chi-squared test. For further investigation, single-cell data from GSE243526 were utilized. For validation, the expression levels of JPT1 and TBRG4 were assessed using RT-qPCR in clinical samples. Genes targeting E2F, such as AURKB, JPT1, TBRG4, and KIF4A, showed increased expression linked to poor patient prognosis, regardless of clinical features. Kaplan-Meier survival analysis revealed that elevated expression of these genes correlated significantly with decreased survival rates and heightened mortality risk. Single-cell data confirmed that candidate genes exhibited higher expression in tumor-associated epithelial cells than healthy ones. Furthermore, samples from group C1 exhibited a lower survival rate than C2. Immune cell infiltration analysis determined that high expression of E2F target genes in the C1 subgroup was associated with diminished T cell infiltration and increased PD-L1 and PD-L2 expression. A strong and significant association was also identified between triple-negative breast cancer and the C1 cluster. RT-qPCR validation confirmed a significant elevation of JPT1 and TBRG4 expression levels relative to adjacent healthy tissues in BC. These findings suggest that E2F target genes, including JPT1 and TBRG4, may act as prognostic biomarkers and contribute to immune evasion in BC. E2F target genes can also offer good potential for classifying and treating patients.
- 6 June 2025
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-14
Open AccessInsights into the E2F target genes in breast cancer: associations of pathway genes with prognosis and immune cell filtration based on in silico and ex vivo analyses
E2F transcription factors are crucial in various biological processes, including cell proliferation, differentiation, and apoptosis. However, the exact role of E2F target genes in breast cancer (BC), as well as their influence on survival and immune response, remains poorly understood. To investigate the differential expression of E2F target genes and their relationship with patient prognosis and immune cell infiltration, transcriptomic data from the Cancer Genome Atlas database were analyzed. A risk model was developed to identify genes associated with survival. BC samples were clustered into high-expression (C1) and low-expression (C2) groups of E2F target genes. The correlation between gene expression and factors such as survival, immune cell infiltration (CD4 + and CD8 + T cells), and immune checkpoint inhibitors (PD-L1 and PD-L2) was analyzed. We analyzed the link between clusters and clinical characteristics using the chi-squared test. For further investigation, single-cell data from GSE243526 were utilized. For validation, the expression levels of JPT1 and TBRG4 were assessed using RT-qPCR in clinical samples. Genes targeting E2F, such as AURKB, JPT1, TBRG4, and KIF4A, showed increased expression linked to poor patient prognosis, regardless of clinical features. Kaplan-Meier survival analysis revealed that elevated expression of these genes correlated significantly with decreased survival rates and heightened mortality risk. Single-cell data confirmed that candidate genes exhibited higher expression in tumor-associated epithelial cells than healthy ones. Furthermore, samples from group C1 exhibited a lower survival rate than C2. Immune cell infiltration analysis determined that high expression of E2F target genes in the C1 subgroup was associated with diminished T cell infiltration and increased PD-L1 and PD-L2 expression. A strong and significant association was also identified between triple-negative breast cancer and the C1 cluster. RT-qPCR validation confirmed a significant elevation of JPT1 and TBRG4 expression levels relative to adjacent healthy tissues in BC. These findings suggest that E2F target genes, including JPT1 and TBRG4, may act as prognostic biomarkers and contribute to immune evasion in BC. E2F target genes can also offer good potential for classifying and treating patients.
- 5 April 2025
- Published by Elsevier in Brain Research
- Vol. 1857, 149599
Alterations in NFAT5 and ATP6V1E1 expression as potential diagnostic biomarkers in blood and brain for Alzheimer’s disease: A study of gene overlap
- 5 April 2025
- Published by Elsevier in Brain Research
- Vol. 1857, 149599
Alterations in NFAT5 and ATP6V1E1 expression as potential diagnostic biomarkers in blood and brain for Alzheimer’s disease: A study of gene overlap
- 30 August 2024
- Published by Springer Nature in Biochemical Genetics
- Vol. 63 (5) , 3845-3862
Therapeutic Potential of PLK1, KIF4A, CDCA5, UBE2C, CDT1, SKA3, AURKB, and PTTG1 Genes in Triple-Negative Breast Cancer: Correlating Their Expression with Sensitivity to GSK 461364 and IKK 16 Drugs
The treatment of triple-negative breast cancer (TNBC) has been associated with challenges due to the lack of expression of ER, PR, and HER2 receptors in tumor cells. This study aimed to identify genes with potential therapeutic targets in TNBC. Data from the cancer genome atlas regarding breast cancer (BC) were downloaded. After initial preprocessing, cancer samples were categorized into four groups: TNBC, HER2-positive, luminal A, and luminal B. Gene expression differences between these groups were calculated, focusing on genes that showed differential expression in TNBC. A protein–protein interaction network was conducted to identify hub genes among the candidate genes related to TNBC. The protein expression of candidate genes was assessed using immunohistochemistry data from the human protein atlas. Drug resistance and sensitivity associated with hub genes were identified using data from PharmacoDB. TNBC samples and the RT-qPCR method were used to confirm the results. Our findings revealed that eight genes, namely PLK1, KIF4A, CDCA5, UBE2C, CDT1, SKA3, AURKB, and PTTG1, had significant upregulation at the RNA level in TNBC subgroup compared to other subgroups and could be considered hub genes in TNBC. Compared to other subgroups, their expression level in TNBC samples had high sensitivity and specificity. RT-qPCR results also demonstrated a significant increase in levels of SKA3 and PTTG1 in the TNBC compared to healthy tissue and other subgroups. The protein expression of these genes was notably high in some BC samples. PharmacoDB data showed that some candidate genes were closely linked to drug sensitivity of GSK 461364 and IKK 16. The results of this study showed a significant increase in the expression level of PLK1, KIF4A, CDCA5, UBE2C, CDT1, SKA3, AURKB, and PTTG1 in TNBC compared to other BC subgroups. These genes show considerable promise as therapeutic targets for the TNBC subgroup.
- 30 August 2024
- Published by Springer Nature in Biochemical Genetics
- Vol. 63 (5) , 3845-3862
Therapeutic Potential of PLK1, KIF4A, CDCA5, UBE2C, CDT1, SKA3, AURKB, and PTTG1 Genes in Triple-Negative Breast Cancer: Correlating Their Expression with Sensitivity to GSK 461364 and IKK 16 Drugs
The treatment of triple-negative breast cancer (TNBC) has been associated with challenges due to the lack of expression of ER, PR, and HER2 receptors in tumor cells. This study aimed to identify genes with potential therapeutic targets in TNBC. Data from the cancer genome atlas regarding breast cancer (BC) were downloaded. After initial preprocessing, cancer samples were categorized into four groups: TNBC, HER2-positive, luminal A, and luminal B. Gene expression differences between these groups were calculated, focusing on genes that showed differential expression in TNBC. A protein–protein interaction network was conducted to identify hub genes among the candidate genes related to TNBC. The protein expression of candidate genes was assessed using immunohistochemistry data from the human protein atlas. Drug resistance and sensitivity associated with hub genes were identified using data from PharmacoDB. TNBC samples and the RT-qPCR method were used to confirm the results. Our findings revealed that eight genes, namely PLK1, KIF4A, CDCA5, UBE2C, CDT1, SKA3, AURKB, and PTTG1, had significant upregulation at the RNA level in TNBC subgroup compared to other subgroups and could be considered hub genes in TNBC. Compared to other subgroups, their expression level in TNBC samples had high sensitivity and specificity. RT-qPCR results also demonstrated a significant increase in levels of SKA3 and PTTG1 in the TNBC compared to healthy tissue and other subgroups. The protein expression of these genes was notably high in some BC samples. PharmacoDB data showed that some candidate genes were closely linked to drug sensitivity of GSK 461364 and IKK 16. The results of this study showed a significant increase in the expression level of PLK1, KIF4A, CDCA5, UBE2C, CDT1, SKA3, AURKB, and PTTG1 in TNBC compared to other BC subgroups. These genes show considerable promise as therapeutic targets for the TNBC subgroup.